COX-2 – a target for preventing hepatic carcinoma?

Bibliography

• RONNIE TUNG-PING P,SHEUNG-TAT F, CHUNG-MAU L et al: Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann. Surg. (2001) 234:63–70.
   PubMedGoogle Scholar
• DOMINGUEZ-MALAGON H, GAYTAN-GRAHAM S: Hepatocellular carcinoma: an update. Ultrasmuct. PathoL (2001) 25:497–516.
   PubMed Web of Science ®Google Scholar
• ••Thorough review of HCC.
   Google Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 87:803–809.
   PubMed Web of Science ®Google Scholar
• •Animal model of COX-2.
   Google Scholar
• KAWAMORI T, RAO CV,SEIBERT K et al: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. (1998) 58:409–412.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM,PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitorn in familial adenomatous polyposis. N Engl. I Med. (2000) 342:1946–1952.
   Google Scholar
• O'NEIL GP, FORD-HUTCHINSON AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. (1993) 330:156–160.
   PubMed Web of Science ®Google Scholar
• SUSAN BA, ARI R, KAREN Net al.: Structure of the human cyclo-oxygenase-2 gene. Biochemical (1994) 302:723–727.
   Google Scholar
• SHENG H, SHAO J, DUBOIS RN: K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase Bl. Cancer Res. (2001) 61:2670–2675
   PubMed Web of Science ®Google Scholar
• •Mechanism of COX-2.
   Google Scholar
• SASAHARA Y, MUTOH M, TAKAHASHI M et al: Suppression of promoter-dependent transcriptional activity of inducible nitric oxide synthase by sodium butyrate in colon cancer cells. Cancer Lett. (2002) 177:155–161.
   PubMedGoogle Scholar
• PEREZ-SALA D, LAMAS S: Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid. Redox Signal (2001) 3:231–248.
   PubMed Web of Science ®Google Scholar
• KEENE JD: Why is Hu where? Shuttling ofearly-response-gene messenger RNA subsets. Proc. Nati Acad. Sci. USA (1999) 96:5–7.
   PubMed Web of Science ®Google Scholar
• DAN AD, NEAL DT, PETER HK et al.:Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. Clin. Invest. (2001) 108:1657–1665.
   Google Scholar
• LOWELL GS, WAN Z, STEPHEN WS: Androgen regulates the level and subcellular distribution of the AU-rich ribonucleic acid-binding protein HuR both M vitro andM vivo. Endocrinology(2001) 142:2361–2368.
   PubMedGoogle Scholar
• TANG Q, GONZALES M,INOUE H et al: Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res. (2001) 61:4329–4332.
   PubMedGoogle Scholar
• VICTOR DL, HAILLING L, FAN Z et al:Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes. Carcinogenesis (2002) 23:73–79.
   PubMedGoogle Scholar
• •Regulation of COX-2 in hepatocytes.
   Google Scholar
• NANJI AA, JOKELAINEN K,TIPOE GL et al.: Dietary saturated fatty acids reverse inflammatory and fibrotic changes in ratliver despite continued ethanol administration. I PharmacoL Exp. The]: (2001) 299:638–644.
   Google Scholar
• GALLOIS C, HABIB A, TAO Jet al.: Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J. Biol. Chem. (1998) 273:23183–23190.
   Google Scholar
• •Role of NF-KB on COX-2.
   Google Scholar
• CARMELIET P, DORIY,HERBERT JM et al.: Role of HIF-la in hypwda-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature (1998) 394:485–490.
   Google Scholar
• RUDNICK DA, PERLMUTTER DH, MUGLIA LJ: Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc. Nati Acad. Sri. USA (2001) 98:8885–8890.
   PubMedGoogle Scholar
• ••Role of PGs in liver regeneration.
   Google Scholar
• RAHMAN MA, DHAR DK,YAMAGUCHI E et al.: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis Cvirus-positive cases. Clin. Cancer Res. (2001) 7:1325–1332.
   Google Scholar
• ••Relationship between COX-2 and iNOS inHCV-positive HCC.
   Google Scholar
• KIMURA H, NAKAJIMA T,KAGAWA K et al.: Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver (1998) 18:14–19.
   Google Scholar
• MAZZANTI R, MESSERINI L, MONSACCHI L et al.: Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology (1997) 25:229–234.
   PubMed Web of Science ®Google Scholar
• ••HCV-induced HCC and angiogenesis.
   Google Scholar
• LIN MT, LEE RC, YANG PC et al: Cyclooxygenase-2 inducing Mc1-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. (2001) 276:48997–49002.
   Google Scholar
• SHENG H, SHAO J,O'MAHONY CA et aL: Transformation of intestinal epithelial cells by chronic TGF-betal treatment results in downregulation of the Type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene (1999) 18:855–867.
   PubMedGoogle Scholar
• PJ MOOS, EDES K, FITZPATRIC FA: Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc. Nati Acad. Sri. USA (2000) 97:9215–9220.
   PubMedGoogle Scholar
• TAKAHASHI M, SAITO H,OKUYAMA T et al: Overexpression of Bc1-2 protects human hepatoma cells from Fas-antibody-mediated apoptosis.HepatoL (1999) 31:315–322.
   Google Scholar
• SCHUSTER R, GERLICH WH, SCHAEFER S: Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts. Oncogene (2000) 19:1173–1180.
   PubMedGoogle Scholar
• UENO T, HASHIMOTO 0,KIMURA R et al: Relation of Type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma. Int. J. Oncol (2001) 18:49–55.
   PubMedGoogle Scholar
• •TGF-P in HCC.
   Google Scholar
• TERAMOTO T, SATONAKA K, KITAZAWA S et al.: p53 gene abnormalities are closely related to hepatoviral infections and occur at a latestage of hepatocarcinogenesis. Cancer Res. (1994) 54:231-235.Effect of p53 gene abnormalities in HCC.
   Google Scholar
• HUNG WC, CHANG HC,PAN MR et al.: Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Ma Pharmacol (2000) 58:1398–1403.
   Google Scholar
• FIORENTINO M, ALTIMARI A, D'ERRICO A et al.: Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin. Cancer Res. (2000) 6:3966–3972.
   Google Scholar
• ••Role of p27 in HCC.
   Google Scholar
• QIAO L, LEACH K,MCKINSTRY R et al.: Hepatitis B virus X protein increases expression of p21(Cip-1/ WAF1/MDA6) and p27 (Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology(2001) 34:906–917.
   Google Scholar
• SPEIR E, YU ZX, FERRANS VJ et al: Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ. Res. (1998) 83:210–216.
   PubMedGoogle Scholar
• OKUDA M, LI K, BEARD MR et al: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology (2002) 122:366–375.
   PubMed Web of Science ®Google Scholar
• ••New findings of HCV core protein in thedevelopment of HCC.
   Google Scholar
• TSUJII M, DUBOIS RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 83:493–501.
   PubMed Web of Science ®Google Scholar
• ENDO K, UEDA T, UEYAMA J et al: Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum. Pathol (2000) 31:558–565.
   PubMed Web of Science ®Google Scholar
• ACHIWA H, YATABE Y, HIDA T et al:Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. (1999) 5:1001–1005.
   PubMed Web of Science ®Google Scholar
• MASUNAGA R, KOHNO H,DHAR DK et al: COX-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Gin. Cancer Res. (2000) 6:4064–4068.
   Google Scholar
• MARNETT LJ: Aspirin and the potential role of prostaglandin in colon cancer. Cancer Res. (1992) 52:5575–5589.
   PubMed Web of Science ®Google Scholar
• SUBBEGOWDA R, FROMMEL TO: Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res. (1998) 58:2772–2776.
   PubMedGoogle Scholar
• EDWARD G, ERIC BR, MEIR JS et al: Aspn use and the risk for colorectal cancer and adenoma in male health professionals. Ann. hat. Med. (1994) 121:241–246.
   Google Scholar
• DUBOIS RN: Cyclooxygenase - a target for colon cancer prevention. Aliment Pharmacol Ther. (2000) 14:64–67.
   PubMedGoogle Scholar
• ••An outline of colon cancer prevention.
   Google Scholar
• HSU AL, CHING TT, WANG DS et al: The cyclooxygenase-2 inhibitor celecoxib induce apoptosis by blocking Akt activation in human prostate cancer cells independently of Bc1-2. I. Biol. Chem. (2000) 275:11397–11403.
   Google Scholar
• ••Describes the mechanism of a COX-2inhibitor.
   Google Scholar
• SMALLEY W, GRIFFIN MR,FOUGHT RL et al.: Excess costs from gastrointestinal disease associated with nonsterodal anti-inflammatory drugs. J. Gen. hat. Med. (1996) 11:461–469.
   Google Scholar
• GOSHI N, SYUNSUKE Y,HIROMI M et al.: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. fpn J. Can. Res. (1999) 90:1152–1162.
   Google Scholar
• PENTLAND AP, SCHOGGINS JW, SCOTT GA et al.: Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis (1999) 20: 1939-1944.
   Google Scholar
• GRUBBS CJ, LUBET RA, KOKI AT et al.: Celecoxib inhibits N-butyl-N-(4-hydroxybuty1)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. (2000) 60:5599–5602.
   PubMed Web of Science ®Google Scholar
• ••Effect of a COX-2 inhibitor in urinarybladder cancer.
   Google Scholar
• MASFERRERJL, LEAHY KM, KOKI AT et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60:1306–1311.
   PubMed Web of Science ®Google Scholar
• ••Establishes the antiangiogenic effect ofCOX-2 inhibitors.
   Google Scholar
• LIU XH, KIRSCHENBAUM A,YAO S et al.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. (2000) 164:820–825.
   Google Scholar
• CHANG HC, WENG CF: Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep. (2001) 8:1321–1325.
   PubMed Web of Science ®Google Scholar
• WILLIAMS CS, SHENG H,BROCKMAN JA et al.: A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia (2001) 3:428–436.
   Google Scholar
• DENDA A, KITAYAMA W,MURATA A et al: Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis (2002) 23:245–256.
   PubMedGoogle Scholar
• ••Describes a new animal model to evaluatethe role of COX-2 in hepatocarcinogenesis.
   Google Scholar
• BAYER BM, BEAVEN MA: Evidence that indomethacin reversib inhibits growth in the G1 phase of the cell cycle. Biochem. Pharmacol (1979) 28:441–443.
   PubMed Web of Science ®Google Scholar
• RAHMAN MA, DHAR DK,MASUNAGA R et al.: Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res. (2000) 60:2085–2089.
   Google Scholar
• •Effect of NSAIDs in HCC.
   Google Scholar
• BAE SH, JUNG ES, PARK YM et al.: Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin. Can. Res. (2001) 7:1410–1418.
   PubMed Web of Science ®Google Scholar
• ••Antiproliferative effect of NS-398 onhuman hepatoma cells.
   Google Scholar
• NIKITAKIS NG, HEBERT C,LOPES MA et al.: PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int. J. Cancer (2002) 98:817–823.
   Google Scholar
• •NSAIDs and PPAR.
   Google Scholar
• KARIN H, WOLFRAM P,BRIGITTE M et al.: Role of transforming growth factor and prostaglandins in preferential growth of preneoplastic rat hepatocytes. Carcinogenesis (2001) 22:1247–1256.
   Google Scholar
• ABIRU S, NAKAO K, ICHIKAWA T et al.: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology (2002) 35:1117–1124.
   Google Scholar
• ••New findings of a COX-2 inhibitor inHCC.
   Google Scholar
• CALLEJAS NA, CASADO M,BOSCA L et al.: Absence of nuclear factor KB inhibition by NSAIDs in hepatocytes. Hepatology (2002) 35:341–348.
   Google Scholar
• ••Relationship between NSAIDs and NE-0in HCC.
   Google Scholar
• GATELY S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev (2000) 19:19–27.
   PubMed Web of Science ®Google Scholar
• NIES AT, KONIG J,PFANNSCHMIDT M et al.: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer (2001) 94:492–499.
   Google Scholar
• CHENIVESSE X, FRANCO D, BRECHOT C: MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J. Hepatology (1993) 18:168–172.
   PubMedGoogle Scholar
• ZIEMANN C, SCHAFER D, RUDELL G, KAHL GE HIRSCH-ERNEST KI: The cyclooxygenase system participates in functional mdrlb overexpression in primary rat hepatocyte cultures. Hepatology (2002) 35:579–588.
   PubMed Web of Science ®Google Scholar
• ••COX system and mdr 1 gene.
   Google Scholar
• FANTAPPIE 0, MASINI E,SARDI I et al.: The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology (2002) 35:843–852.
   Google Scholar
• ••Role of mdr 1 in the up-regulation ofCOX-2 in HCC.
   Google Scholar
• KAWAI HF, KANEKO S,HONDA M et al.: Alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology (2001) 33:676–691.
   Google Scholar
• ZHU W, SMITH A, YOUNG CY: A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology (1999) 140:5451–5454.
   PubMed Web of Science ®Google Scholar
• TEJURA S, RODGERS GR,DUNION MH et al.: Sex-steroid receptors in the diethylnitrosamine model of hepatocarcinogenesis: modifications by gonadal ablation and steroid replacementtherapy.Endocrinol (1989) 3:229–237.
   Google Scholar
• NAGASUE N, YUKAYA H,CHANG YC et al: Active uptake of testosterone by androgen receptors of hepatocellular carcinoma in humans. Cancer (1986) 57:2162–2167.
   PubMedGoogle Scholar
• MARUYAMA S, NAGASUE N,DHAR DK et al: Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clio. Cancer Res. (2001) 7:2096–2104.
   PubMedGoogle Scholar
• SU LK, ABDALLA EK, LAW CH, KOHLMANN W, RASHIDA,VAUTHEY JN: Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer (2001) 92:332–339.
   PubMed Web of Science ®Google Scholar
• WEIHRAUCH M, BENICKE M, LEHNERT G, WITTEKIND C, WRBITZKY R, TANNAPFEL A: Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br: J. Cancer (2001) 84:982–989.
   Google Scholar
• DEMPKE W, RIE C, GROTHEY A, SCHMOLL HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? Cancer Res. Clio. °pea (2001) 127:411–417.
   Google Scholar
• •Reviews COX-2 and cancer prevention.
   Google Scholar
• FUJITA M, FUKUI H, KUSAKA T et al: Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J. Gastroenterol Hepatol (2000) 15:1277–1281.
   PubMedGoogle Scholar
• ZHANG Z, DUBOIS RN: Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology (2000) 118:1012–1017.
   PubMed Web of Science ®Google Scholar
• •NSAIDs regulate Par-4 gene.
   Google Scholar
• KONDO M, YAMAMOTO H, NAGANO H et al.: Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clio. Cancer Res. (1999) 5:4005–4012.
   PubMedGoogle Scholar
• ••Evaluates the involvement of COX-2 inHCC.
   Google Scholar
• KOJIMA M, MORISAKI T,UCHIYAMA A et al.: Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann. Sorg. °pea (2001) 8:458–465.
   Google Scholar
• KOGA H, SAKISAKA S,OHISHI M et al.: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 29:688–696.
   Google Scholar
• ••As above.
   Google Scholar
• TRIFAN OC, SMITH RM, THOMPSON BD, TIMOTHY HLA: Overexpression of cyclooxygenase-2 induces cell cycle arrest. J. Biol. Chem. (1999) 274:34141–34147.
   PubMedGoogle Scholar
• ••A novel mechanism of COX-2.
   Google Scholar
• CALLEJAS NA, BOSCA L,WILLIAMS CS et al. Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins. Gastroenterology (2000) 119:493–501.
   Google Scholar
• ••A new mechanism of COX-2 in HCC.
   Google Scholar
• XU L, HUI L, WANG S et al: Expressionprofiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. (2001) 61:3176–3181.
   PubMed Web of Science ®Google Scholar